BiologicalDrug
Inodiftagene vixteplasmid clinical trials
Also written BC-819.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Anchiano Therapeutics Israel Ltd. (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses inodiftagene vixteplasmid is read from its arms, and is right about nine times in ten.
Testing it · 3
- Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBCTerminatedPhase 2Anchiano Therapeutics Israel Ltd.NCT03719300Written as inodiftagene vixteplasmid
- Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic AdenocarcinomaTerminatedPhase 2Anchiano Therapeutics Israel Ltd.NCT01413087Written as Biological/Vaccine: BC-819
- Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian CancerCompletedPhase 1/2Anchiano Therapeutics Israel Ltd.NCT00826150Written as BC-819
Codes
What other systems call inodiftagene vixteplasmid · ClinicalTrials.gg INT015824
- UNII (FDA) 98YK326XZ6INODIFTAGENE VIXTEPLASMIDOne source FDA
- NCI Thesaurus C157333Inodiftagene VixteplasmidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 98YK326XZ6 | INODIFTAGENE VIXTEPLASMID | One source FDA |
| NCI Thesaurus | C157333 | Inodiftagene Vixteplasmid | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.